Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- GI Grand Rounds lecture – GI 2.0: From Procedures to Pathways
- Gastroenterology Practice Economics: Benchmark 2026 (Jiro Health)
- Surgery Partners to be taken private by Bon Secours affiliate in $5.7 billion deal (Reuters)
- Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians (Guardant Health)
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer (Genmab)
- Do Wearables in GI Care Provide Useful Data or Fuel Anxiety? (Medscape)
- APPs Poised to Level the Playing Field for Rural Patients With IBD (GI & Endoscopy News)
- Improve IBD bowel checks for early cancer detection, study finds (Eurekalert)
